抗抑郁药米氮平对吉西他滨治疗胰腺癌模型的辅助作用

目的 探讨抗抑郁药米氮平对吉西他滨治疗的胰腺癌移植瘤裸鼠进食量、体重和肿瘤生长的影响.方法 24只胰腺癌裸鼠皮下移植瘤模型随机分为对照组、吉西他滨组(术后第1、4、7、10天腹腔注射吉西他滨100 mg/kg体重)和联用组(吉西他滨组+米氮平10 mg·kg~(-1)·d~(-1)灌胃,持续21曲,每组8只.术后21 d处死裸鼠,比较3组动物体重、进食量、肿瘤体积的变化.结果 吉西他滨组具有显著的抗肿瘤生长作用,但存在显著的胃纳减少和体重降低等不良反应.术后第21天,联用组和吉西他滨组胰腺癌移植瘤体积无明显差异,抑瘤率分别为69.13%和71.60%(P>0.05);联用组进食量(3.12±0.11)g、体重(14.68±0.42)g,稍高于吉西他滨组的(2.96±0.14)g和(14.38±0.61)g(P值均>0.05),但显著低于对照组的(4.65±0.13)g和(17.46±0.52)g(P值均<0.05).结论 吉西他滨化疗具有显著的抗胰腺癌作用,米氮平虽无显著增效作用,但可在一定程度上减轻大剂量吉西他滨化疗的不良反应.

Adjunctive effects of Mirtazapine in nude mice with pancreatic cancer xenografts treated with Gemcitabine

Objective To investigate the effects of mirtazapine in combination with gemcitabine on food intake,body weight and tumor growth of human pancreatic carcinoma xenografts in nude mice.Methods 24 subcutaneous pancreatic cancer xenograft nude mice were randomly divided into control group,gemcitabine group(receiving 100 mg/kg gemcitabine i.P.on days 1,4,7 and 10 after operation)and combination group (gemcitabine as above and mirtazapine,10 mg·kg~(-1)·d~(-1),orally feeding for 21 days),with 8 mice in each group. All mice were sacrificed at day 21.Food intake,body weight and tumor size were compared among three groups.Results Gemcitabine group showed significant anti-tumor effects,but adverse effects such as decreasing food intake and body weight Was also noted. On days 21,there Was no significant difference in tumor size between combination group and gemcitabine group.The tumor inhibition rates of the two groups were 69.13%and 71.60%respectively(P>0.05).The food intake of mice and body weight[(3.12±0.11)g and(14.68±0.42)g]in combination group were slightly greater than these of gemcitabine group[(2.96±0.14)g and(14.38±0.61)g,P>0.05],but these parameters were significantly lowerthan those of control group[(4.65±0.13)g and(17.46±0.52)g,P<0.05].Conclusions Gemcitabine chemotherapy showed significant anti-tumor effects. Mirtazapine cannot significantly enhance the anti.tumor effect of gemcitabine. However,mirtazapine could alleviate adverse events of gemcitabine to some extent.